<DOC>
	<DOCNO>NCT02411929</DOCNO>
	<brief_summary>This study evaluate absolute oral bioavailability ( F ) fraction absorb ( Fa ) ertugliflozin follow oral administration unlabeled ertugliflozin ( MK-8835 ) intravenous ( IV ) oral administration 14^C-labeled ertugliflozin healthy male participant .</brief_summary>
	<brief_title>A Phase 1 Study Ertugliflozin Healthy Male Participants ( MK-8835-020 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Healthy male subject age 18 65 year . Body Mass Index ( BMI ) 17.5 30.5 kg/m^2 ; total body weight &gt; 50 kg ( 110 lb . ) Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy ) . Any clinically significant malabsorption condition ( eg , gastrectomy , bowel resection ) . A positive urine drug screen drug abuse recreational drug . Positive hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( HCV Ab ) human immunodeficiency virus ( HIV ) result . History abuse alcohol binge drinking and/or illicit drug use dependence within 6 month Screening . Current smoker smoke substance within last 12 month . Treatment investigational drug within 1 month precede first dose study medication . Have participate clinical study exposure 14^C last 12 month . Any radiation exposure , include project result present study , exclude background radiation include diagnostic xrays medical exposure . No occupationally expose worker , define Ionising Radiation Regulation 1999 , shall participate study . Use prescription nonprescription drug ( include vitamin dietary supplement ) within 7 day prior first dose study medication . Use herbal supplement within 28 day prior first dose study medication . Blood donation ( exclude plasma donation ) approximately 1 pint ( 500 mL ) within 56 day prior dose . Participants previously participate clinical trial ertugliflozin . Serious adverse reaction serious hypersensitivity drug formulation excipients .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>